Skip to main content

Radiotherapy: Finance

Question for Department of Health and Social Care

UIN 127529, tabled on 9 December 2020

To ask the Secretary of State for Health and Social Care, how much his Department has allocated for rollout of stereotactic ablative radiotherapy (SABR); and what the planned timescale is for the rollout of SABR.

This answer is the replacement for a previous holding answer.

Answered on

11 January 2021

The Government and NHS England and NHS Improvement are committed to expanding the provision and use of stereotactic ablative radiotherapy (SABR) and has put in place a comprehensive support package to enable trusts to achieve this, including centrally funded access to both the national quality assurance programme and experienced mentors.

The expansion of SABR across the National Health Service is expected to require an investment of around £13 million and NHS England and NHS Improvement have made this available. Our aim is to ensure that by April every part of the country will be offering SABR treatment for non-small cell lung cancer and those with lung, lymph nodes and non-spine bone oligometastatic disease, in radiotherapy units nationwide. Further rollout for other disease types is planned for 2021/22.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.